Skip to main content

Table 2 Average levels of bFGF, pg/ml

From: Predictors of fibrogenesis in children with JIA: a single-center pilot study

Indicator

n

means

SD

SE

min

max

Q25

ME

Q75

Sex

Boys

25

7551.88

3062.34

612.47

4808.33

18,011.25

4988.39

7300.22

8331.84

girls

45

7437.28

2643.30

394.04

4171.56

17,119.83

5649.78

6787.45

8556.67

Age

10–13 y

38

6968.45

1914.40

310.56

4171.56

14,361.1

5559.70

6639.79

7632.24

14–18 y

32

8083.54

3480.40

615.25

4225.58

18,011.25

5530.27

7730.35

8662.84

Age of JIA onset

 < 3 y

9

6217.65

773.18

257.73

4924.41

7471.25

5763.66

6109.17

6787.45

3–5 y

12

7475.90

1686.40

486.82

4171.56

10,505.88

6528.54

7276.15

8721.77

6–10 y

20

8148.82

3213.02

718.45

4808.33

18,011.25

6335.87

7393.79

8840.89

11–14 y

22

6488.29

1606.85

342.58

4225.58

9205.14

4988.39

5594.91

8016.54

15–18 y

7

10,297.98

4928.90

1862.95

5559.70

17,119.83

5559.70

8331.84

17,119.83

Variant

oligo

25

7552.63

2765.49

553.09

4808.33

18,011.25

5530.27

7453.78

8697.72

poly

45

7436.86

2816.12

419.80

4171.56

17,119.83

5559.70

6787.45

8310.03

Duration

< 1 y

11

7300.57

2818.21

849.72

4988.39

14,361.11

4988.39

6563.66

9125.10

1–3 y

26

7812.12

3196.07

626.80

4808.33

17,119.83

5559.70

7483.02

8579.85

˃ 3 y

33

7274.33

2457.76

427.84

4171.56

18,011.25

5959.60

6787.45

8310.03

Disease activity according to JADAS-27

inactive disease

3

6743.29

1112.43

642.26

5959.60

8016.54

5959.60

6253.74

8016.54

low

44

6727.11

1979.52

298.42

4171.56

14,361.1

5420.24

6379.58

7551.74

moderate

19

9364.85

3764.04

863.53

5530.27

18,011.25

7524.14

8331.84

8745.82

high

4

7329.86

2045.81

1022.90

5559.70

9205.14

5559.70

7277.30

9100.02

MTX treatment

not present

18

7386.12

3806.80

897.27

4808.33

17,119.83

4988.39

5559.70

8331.84

present

52

7510.08

2368.693

328.48

4171.56

18,011.25

5982.24

7317.01

8444.26

Dosage of MTX, mg/m2/week

< 10

4

7610.33

1889.73

944.87

5453.17

10,063.10

6453.48

7462.52

8767.18

10–12,5

20

7875.05

2291.38

512.37

4988.39

14,361.11

5744.94

7764.70

8651.25

12,6–15

19

7677.30

2869.74

658.36

4225.59

18,011.25

6253.74

7300.22

8745.83

˃ 15

9

6301.49

1175.63

391.88

4171.56

8697.72

6004.87

6180.64

6536.69

All children with JIA

 

70

7478.205

2778.57

332.10

4171.56

18,011.25

5559.70

6809.27

8331.84

  1. Significant difference was obtained only in the following groups:
  2. Age of JIA onset
  3. (< 3 y. 15–18 y. p = 0.003; 3–5 y. 15–18 y. p = 0.025; 6–10 y. 11–14 y. p = 0.041; 11–14 y. 15–18 y. p = 0.001)
  4. Disease activity according to JADAS-27
  5. (low moderate p = 0.0004)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096